Abstract
BACKGROUND—Small cell lung cancer (SCLC) represents about 20% of primary lung tumours and the costs associated with the management of SCLC can be significant. The main objective of this study was to obtain information on current patterns of care and associated resource use and costs for patients with SCLC from initial diagnosis and treatment phase, throughout disease progression and terminal care. METHODS—A 4 year retrospective patient chart analysis (1994-7) was conducted on a consecutive series of 109 patients diagnosed with SCLC in two Newcastle hospitals. For this consecutive series of patients all details about care received including tests and procedures, treatment, and medication from diagnosis till death were recorded. Pathways of care and forms were designed to enable resource use to be captured for different disease phases. Unit costs were determined from a variety of sources including the Newcastle Hospitals NHS Trust Finance Department and the British National Formulary. RESULTS—The average total cost per patient calculated for the full cohort of 109 patients was £11556. Initial treatment was the most resource use intensive constituting 48.2% of the total cost. The major cost element throughout all disease phases was hospitalisation. Twenty eight percent of the total costs of care occur after recurrence of the disease until death, of which 73% are generated by terminal care. CONCLUSION—The results of this retrospective medical chart analysis show that the costs of care of SCLC are considerable, although the variability between patients in terms of the type and quantity of resource use is very high. Analyses such as this provide a useful insight into resources used in actual clinical practice.
Full Text
The Full Text of this article is available as a PDF (137.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
- Doyle J. J., Dezii C. M., Sadana A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol. 1996 Dec;23(6 Suppl 13):51–60. [PubMed] [Google Scholar]
- Drummond M., Davies L. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. Pharmacoeconomics. 1994;6 (Suppl 2):44–52. doi: 10.2165/00019053-199400062-00008. [DOI] [PubMed] [Google Scholar]
- Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995 Dec;5(4):408–419. [PubMed] [Google Scholar]
- Friedlander M. L., Tattersall M. H. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982 Dec;18(12):1237–1241. doi: 10.1016/0277-5379(82)90124-9. [DOI] [PubMed] [Google Scholar]
- Glaspy J. A., Bleecker G., Crawford J., Stoller R., Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer. 1993;29A Suppl 7:S23–S30. doi: 10.1016/0959-8049(93)90613-k. [DOI] [PubMed] [Google Scholar]
- Goodwin P. J., Feld R., Evans W. K., Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988 Oct;6(10):1537–1547. doi: 10.1200/JCO.1988.6.10.1537. [DOI] [PubMed] [Google Scholar]
- Jelinek J. S., Redmond J., 3rd, Perry J. J., Burrell L. M., Benedikt R. A., Geyer C. A., Peller P. J., Wacks L. L., Wise B. J., Ghaed V. N. Small cell lung cancer: staging with MR imaging. Radiology. 1990 Dec;177(3):837–842. doi: 10.1148/radiology.177.3.2173844. [DOI] [PubMed] [Google Scholar]
- Kwekkeboom D. J., Lamberts S. W., Habbema J. D., Krenning E. P. Cost-effectiveness analysis of somatostatin receptor scintigraphy. J Nucl Med. 1996 Jun;37(6):886–892. [PubMed] [Google Scholar]
- Lyman G. H., Lyman C. G., Sanderson R. A., Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993 Mar 17;85(6):488–493. doi: 10.1093/jnci/85.6.488. [DOI] [PubMed] [Google Scholar]
- Nichols C. R., Fox E. P., Roth B. J., Williams S. D., Loehrer P. J., Einhorn L. H. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol. 1994 Jun;12(6):1245–1250. doi: 10.1200/JCO.1994.12.6.1245. [DOI] [PubMed] [Google Scholar]
- Pashko S., Johnson D. H. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer. Pharmacoeconomics. 1992 Apr;1(4):293–297. doi: 10.2165/00019053-199201040-00006. [DOI] [PubMed] [Google Scholar]
- Richardson G. E., Venzon D. J., Edison M., Brown M., Frame J. N., Ihde D. C., Johnson B. E. Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med. 1993 Feb 8;153(3):329–337. [PubMed] [Google Scholar]
- Rosenthal M. A., Webster P. J., Gebski V. J., Stuart-Harris R. C., Langlands A. O., Boyages J. The cost of treating small cell lung cancer. Med J Aust. 1992 May 4;156(9):605–610. doi: 10.5694/j.1326-5377.1992.tb121456.x. [DOI] [PubMed] [Google Scholar]
- Smith I. E., Evans B. D., Gore M. E., Vincent M. D., Repetto L., Yarnold J. R., Ford H. T. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol. 1987 Feb;5(2):185–189. doi: 10.1200/JCO.1987.5.2.185. [DOI] [PubMed] [Google Scholar]